Enspryng (satralizumab) / Roche  >>  Phase 3
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enspryng (satralizumab) / Roche
SAkuraSky, NCT02028884 / 2013-003752-21: Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Checkmark From Sakurasky trial for neuromyelitis optica spectrum disorder at AAN 2019 [screenshot]
May 2019 - May 2019: From Sakurasky trial for neuromyelitis optica spectrum disorder at AAN 2019 [screenshot]
Checkmark SAkuraSky study for NMOSD at ECTRIMS 2018 [screenshot]
Oct 2018 - Oct 2018: SAkuraSky study for NMOSD at ECTRIMS 2018 [screenshot]
Completed
3
85
Europe, Japan, US, RoW
Satralizumab, SA237, RG6168, RO5333787, Placebo, Baseline Treatment
Hoffmann-La Roche, Chugai Pharmaceutical
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
06/18
12/21
SAkuraStar, NCT02073279 / 2015-005431-41: Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Checkmark Full pivotal data in SAkuraStar trial at ECTRIMS 2019
Sep 2019 - Sep 2019: Full pivotal data in SAkuraStar trial at ECTRIMS 2019
Checkmark From SAkuraStar trial for neuromyelitis optica spectrum disorder at ECTRIMS 2019 [screenshot]
Sep 2019 - Sep 2019: From SAkuraStar trial for neuromyelitis optica spectrum disorder at ECTRIMS 2019 [screenshot]
Checkmark SAkuraStar
More
Completed
3
95
Europe, Canada, US, RoW
Satralizumab, SA237, RG6168, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
10/18
01/22
2020-004436-21: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Generalized Myasthenia Gravis

Ongoing
3
240
Europe
Satralizumab, RO5333787, Injection
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Generalized Myasthenia Gravis (gMG), Myasthenia gravis is a rare neuromuscular disorder that causes weakness in the skeletal muscles. Myasthenia gravis affecting multiple muscle groups throughout the body is called gMG., Diseases [C] - Nervous System Diseases [C10]
 
 
2021-001088-26: A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention Studio clinico, di imaging e sui biomarcatori condotto nel disturbo dello spettro della neuromielite ottica (NMOSD) con Satralizumab come intervento

Not yet recruiting
3
100
Europe
satralizumab, [RO5333787], Solution for injection/infusion in pre-filled syringe, Enspryng
F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Neuromyelitis Optica Spectrum Disorder (NMOSD) Disturbo dello spettro della neuromielite ottica (NMOSD), NMOSD,also known as Devic disease, is a disorder of the brain and spinal cord dominated by inflammation of the optic nerve(optic neuritis)and inflammation of the spinal cord (myelitis). NMOSD,noto anche come malattia di Devic,è un disturbo del cervello e del midollo spinale dominato da infiammazione del nervo ottico (neurite ottica) e dall'infiammazione del midollo spinale (mielite)., Diseases [C] - Nervous System Diseases [C10]
 
 
2019-004092-39: A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquaporin-4 (AQP4) Antibody Positive Neuromyelitis Optica Spectrum Disorder

Not yet recruiting
3
8
Europe
Satralizumab, Ro 533-3787/F01- 06, Solution for infusion in pre-filled syringe, Enspryng
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Neuromyelitis Optica Spectrum Disorder (NMOSD), NMOSD is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04963270 / 2020-004436-21: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Active, not recruiting
3
185
Europe, Canada, Japan, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical
Generalized Myasthenia Gravis
01/24
09/24
NCT04660539 / 2020-003413-35: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Completed
3
119
Europe, Canada, Japan, US, RoW
satralizumab, Enspryng, azathioprine (AZA), non-investigational medicinal product (NIMP), mycophenolate mofetil (MMF), NIMP, oral corticosteroids
Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder
05/24
05/24
NCT05987423: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease

Recruiting
3
120
Europe, Japan, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche
Thyroid Eye Disease, TED
03/25
05/26
SatraGO-2, NCT06106828: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease

Recruiting
3
120
Europe, Canada, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche
Thyroid Eye Disease
05/25
05/26
Cielo, NCT05503264 / 2021-002395-39: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

Recruiting
3
152
Europe, Japan, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical Co.
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
06/25
12/27
Meteoroid, NCT05271409 / 2021-003192-34: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Hourglass Apr 2022 - Jun 2022 : First patient in for P3 METEOROID trial for myelin oligodendrocyte glycoprotein antibody-associated disease
Recruiting
3
152
Europe, Canada, Japan, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
07/26
12/28
SAkuraSun, NCT05199688: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Recruiting
3
8
Europe, US, RoW
Satralizumab
Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder, NMOSD
03/27
09/29

Download Options